Is There a Risk of Atherosclerotic Cardiovascular Disease?

The two PCSK9 monoclonal antibodies, Ali RockyMap and MLocumab had just been FDA approved. The retail pricing at that time was quite costly. And over the subsequent years, these drugs have become increasingly more affordable,. Though still certainly more expensive than generic oral statin therapy.